Sale of QVQ Holdings BV shares -- 121 -------------------------------------------- ------ ------ Net cash used in investing activities (328) (509) -------------------------------------------- ------ ------ Financing activities: Proceeds on share issuance, net of transaction costs 1,507 -- Repayment of leases (801) (715) Proceeds on debenture issuance, net of transaction costs 4,059 -- ---------------------------------------- ------ ------ Net cash provided by (used in) financing activities 4,765 (715) -------------------------------------------- ------ ------ Increase (decrease) in cash during the period 370 (1,794) Foreign exchange (294) (468) Cash -- beginning of the period 3,545 8,366 -------------------------------------------- ------ ------ Cash -- end of the period 3,621 6,104 -------------------------------------------- ------ ------ Cash is comprised of: Cash 3,534 6,017 Restricted cash 87 87 -------------------------------------------- ------ ------ 3,621 6,104 ---------------------------------------- ------ ------ Cash paid for interest -- -- Cash paid for income tax -- -- -------------------------------------------- ------ ------
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210683224/en/
CONTACT:
Investor Relations Contact
investors@ipatherapeutics.com
(END) Dow Jones Newswires
December 10, 2024 08:30 ET (13:30 GMT)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。